Featured Research

from universities, journals, and other organizations

Hormone mimic reduces liver damage caused by common genetic kidney disease

Date:
May 4, 2010
Source:
American Society of Nephrology
Summary:
A hormone mimic called Octreotide may be effective for treating polycystic liver disease (PLD) caused by ADPKD, according to new research. The study is the first clinical trial performed in the United States to test the effects of this agent in PLD.

A hormone mimic called Octreotide may be effective for treating polycystic liver disease (PLD) caused by ADPKD, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The study is the first clinical trial performed in the United States to test the effects of this agent in PLD.

In addition to causing kidney failure, ADPKD also often leads to PLD, a condition characterized by multiple variably-sized cysts in the liver. Octreotide mimics the somatostatin hormone that regulates the secretion of several other hormones in the body. Somatostatin exerts its effects by blocking both the formation of the chemical cyclic AMP and the secretion of fluids by cells, two factors thought to play a role in the development of kidney and liver cystic diseases.

Marie Hogan, MD, PhD (Mayo Clinic College of Medicine) and her colleagues designed a clinical trial to examine whether Octreotide could shrink the cyst-filled livers of patients with PLD. The randomized, double blind, placebo-controlled trial enrolled 42 patients with severe PLD caused by ADPKD (34 patients) or autosomal dominant PLD (8 patients). (Autosomal dominant PLD is a genetic form of PLD not caused by ADPKD.)

Patients received Octreotide or placebo, and treatments were administered as monthly injections.

After one year, liver volume decreased by an average of approximately 5% in patients taking Octreotide but slightly increased (by approximately 1%) in patients taking placebo. Octreotide also had an effect on the diseased kidneys of patients with ADPKD.

Among these patients, total kidney volume remained practically unchanged in the Octreotide group but increased by more than 8% on average in the placebo group.

Kidney function was similar in both groups of patients. Octreotide was well tolerated, and treated individuals reported an improved perception of bodily pain and physical activity.

"In summary, Octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile," said Dr. Hogan.

Study co-authors include Tetyana Masyuk, PhD, Linda Page, Vickie Kubly, Eric Bergstralh, Xujian Li, Bohyun Kim, MD, Bernard King, MD, James Glockner, MD, PhD, David Holmes III, PhD, Sandro Rossetti, MD, PhD, Peter Harris, PhD, Nicholas LaRusso, MD, and Vicente Torres, MD, PhD (Mayo Clinic College of Medicine).

In reviewing the results of Dr. Hogan's study in an accompanying editorial, Robert Schrier, MD (University of Colorado Denver) noted that they support the findings of earlier animal and human studies and give hope that increases in polycystic liver and kidney volume can be attenuated in patients with ADPKD. He added that additional, larger studies are needed to verify the results and to demonstrate whether Octreotide can provide meaningful health benefits to patients.

Disclosures: Funding support for the study was provided by Mayo Foundation for Medical Education and Research and Novartis USA. Dr. Hogan received partial funding support for this study from Novartis USA. Dr. LaRusso and Dr, Masyuk are named inventors on pending patent applications filed by Mayo Clinic claiming methods for using somatostatin analogs to treat polycystic liver disease. Dr. Schrier, the author of the editorial, is a consultant for Otsuka Pharmaceuticals.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal References:

  1. Marie C. Hogan, Tetyana V. Masyuk, Linda J. Page, Vickie J. Kubly, Eric J. Bergstralh, Xujian Li, Bohyun Kim, Bernard F. King, James Glockner, David R. Holmes III, Sandro Rossetti, Peter C. Harris, Nicholas F. LaRusso, and Vicente E. Torres. Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of the American Society Nephrology, 2010; DOI: 10.1681/ASN.2009121291
  2. Robert W. Schrier. Randomized Intervention Studies in Human Polycystic Kidney and Liver Disease. Journal of the American Society Nephrology, 2010 DOI: 10.1681/ASN.2010030262

Cite This Page:

American Society of Nephrology. "Hormone mimic reduces liver damage caused by common genetic kidney disease." ScienceDaily. ScienceDaily, 4 May 2010. <www.sciencedaily.com/releases/2010/04/100429172958.htm>.
American Society of Nephrology. (2010, May 4). Hormone mimic reduces liver damage caused by common genetic kidney disease. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2010/04/100429172958.htm
American Society of Nephrology. "Hormone mimic reduces liver damage caused by common genetic kidney disease." ScienceDaily. www.sciencedaily.com/releases/2010/04/100429172958.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins